Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17

Rhea-AI Filing Summary

Janux Therapeutics Vice President of Accounting Maria Dobek reported an open-market sale of 2,038 shares of Janux Therapeutics common stock at $14.17 per share on May 11, 2026. After this transaction, she continues to hold 32,270 shares directly.

Insider Trade Summary

Net Seller: 2,038 shares ($28,878)

Net Sell 1 txn

Insider Dobek Maria

Role Vice President, Accounting

Sold 2,038 shs ($29K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,038	$14.17	$29K

Holdings After Transaction: Common Stock — 32,270 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 2,038 shares Sale price per share: $14.17 per share Shares held after sale: 32,270 shares +1 more

4 metrics

Shares sold 2,038 shares Open-market sale on May 11, 2026

Sale price per share $14.17 per share Common Stock transaction

Shares held after sale 32,270 shares Direct ownership following transaction

Net buy/sell shares -2,038 shares Net direction for this Form 4

Key Terms

open-market sale, Common Stock, transaction code, direct ownership

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code financial

"transaction_code: "S" indicates a sale"

direct ownership financial

"ownership_type: "direct"; total shares following transaction 32,270"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/13/2026 - 08:00 PM Accepted by SEC EDGAR 05/13/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dobek Maria

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Accounting

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S		2,038	D	$14.17	32,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ James Pennington, Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Janux Therapeutics (JANX) report?

Janux Therapeutics reported that Vice President of Accounting Maria Dobek sold 2,038 shares of common stock in an open-market transaction at $14.17 per share, and now holds 32,270 shares directly following the sale.

Who is the insider involved in the recent JANX Form 4 filing?

The insider is Maria Dobek, Vice President of Accounting at Janux Therapeutics. She reported an open-market sale of 2,038 shares of common stock and now directly owns 32,270 shares after the reported transaction.

How many Janux Therapeutics shares did Maria Dobek sell?

Maria Dobek sold 2,038 shares of Janux Therapeutics common stock. The sale was reported as an open-market transaction with a Form 4 filing and reflects a reduction from her previously higher direct holdings.

At what price were the JANX shares sold by Maria Dobek?

The 2,038 Janux Therapeutics shares were sold at an average price of $14.17 per share. This per-share price is taken directly from the reported Form 4 transaction details for the open-market sale.

How many Janux Therapeutics shares does Maria Dobek hold after the sale?

After the reported sale, Maria Dobek directly holds 32,270 shares of Janux Therapeutics common stock. This post-transaction holding figure is explicitly stated in the Form 4 as the total shares following the transaction.